Bank Of America Corp Oncternal Therapeutics, Inc. Transaction History

Bank Of America Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.28 - $0.64 $1,670 - $3,817	-5,965 Reduced 99.42%	35 $0
Q2 2023 Aug 14, 2023	SELL	$0.28 - $0.79 $568 - $1,605	-2,032 Reduced 25.3%	6,000 $2,000
Q1 2023 May 12, 2023	BUY	$0.63 - $1.3 $612 - $1,263	972 Added 13.77%	8,032 $6,000
Q4 2022 Feb 10, 2023	BUY	$0.86 - $22.2 $51 - $1,332	60 Added 0.86%	7,060 $7,000
Q3 2022 Nov 14, 2022	SELL	$0.83 - $17.8 $4,853 - $104,094	-5,848 Reduced 45.52%	7,000 $6,000
Q2 2022 Aug 12, 2022	SELL	$0.7 - $1.56 $14,258 - $31,775	-20,369 Reduced 61.32%	12,848 $14,000
Q1 2022 May 16, 2022	SELL	$1.37 - $2.43 $44,375 - $78,710	-32,391 Reduced 49.37%	33,217 $46,000
Q4 2021 Feb 08, 2022	BUY	$2.27 - $4.39 $17,658 - $34,149	7,779 Added 13.45%	65,608 $149,000
Q3 2021 Nov 15, 2021	BUY	$3.37 - $4.76 $8,502 - $12,009	2,523 Added 4.56%	57,829 $241,000
Q2 2021 Sep 13, 2021	BUY	$4.75 - $9.39 $262,703 - $519,323	55,306 New	55,306 $263,000

362K

Ticker ONCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,517,200
Market Cap $29.4M
Description
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a smal...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.